• EURAP study. An International Antiepileptic Drugs and Pregnancy Registry” (International concerted Action on the Teratogenesis of Anti-epileptic Drugs) (http://www.eurapinternational.org/): Silje Alvestad and Kari Mette Lillestølen, National coordinators
  • E-PILEPSY” is a Pan European Project, with the primary aim of improving awareness and accessibility of surgery for epilepsy across different countries. Epilepsy surgery is an established treatment in the management of individuals with drug resistant focal epilepsy (http://www.e-pilepsy.eu/). Morten I. Lossius, associated partner
  • Nordic prospective observational study of outcomes after rare epilepsysurgery procedures”. Fridny Heimsdottir
  • TRACE («Transcutan VNS (t-VNS) for drug resistant epilepsy»). Oliver Henning, Konstantin Kostov
  • Pharmacokinetic variability, efficacy and tolerability of a new antiepileptic drug, brivaracetam”. Scandinavian project between the National Center for Epilepsy in Norway and Denmark (Filadelfia, Dianalund). Torleiv Svendsen, medical leader, Cecilie J. Landmark, project leader
  • Children with refractory epilepsy and use of the newest antiepileptic drugs”. Scandinavian project between the National Centre for Epilepsy in Norway and Denmark (Filadelfia, Dianalund). Margrete Larsen Burns, Marina Nikoronova, responsible in Denmark, and Cecilie J. Landmark, project leader
  • EDDI EMG triggered seizure seizure alarm”. Oliver Henning in cooperation with Danish Epilepsy Center Dianalund
  • Scandinavian multi-registry study of antiepileptic drug teratogenicity: the SCAN-A study”. Silje Alvestad, post-doc, in cooperation with UiB/Haukeland)

Pharma-sponsored projects

  • Tosca. Novartis. Prot.No CRAD001MIC03: “TuberOus SClerosis Registry to IncreAse Disease Awareness”. International multicenter study. Marit Bjørnvold, Principle Investigator, and  Caroline Lund
  • EXIST-3. Novartis (everolimus). Prot.No. CRAD001M2304: “A three-arm, randomized, double-blind, placebo-controlled study of 2 trough-ranges of evereolimus as adjunctive therapy in patients with tuberous schlerosis complex (TSC) who have refractory partial-onset seizures”. International multicenter study. Marit Bjørnvold, Principle Investigator Caroline Lund
 
Page visits: 110